Alcobra Ltd Now Covered by Analysts at Stifel Nicolaus (ADHD)
Investment analysts at Stifel Nicolaus initiated coverage on shares of Alcobra Ltd (NASDAQ:ADHD) in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $27.00 price target on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 58.26% from the company’s current price.
The analysts wrote, “We are initiating coverage of Alcobra Ltd. with a Buy rating and $27 target price. Alcobra is developing novel and differentiated therapies for cognitive symptoms in various CNS disorders, initially targeting attention deficit hyperactivity disorder (ADHD). The company is approaching Phase III clinical trials with lead compound (MG01CI), which if successful, could be a best-in-class non-stimulant with psychostimulants competitive efficacy, superior side effect profile and specific utility in predominantly inattentive ADHD patients. Additionally, MG01CI could treat cognitive symptoms for multiple other CNS conditions and Alcobra is initiating a program to treat cognitive symptoms in Fragile X syndrome (viewed as a call option). We believe Alcobra is on the verge of bringing truly effective products to a large market, side-stepping many shortcomings of current therapies.”
Separately, analysts at Aegis raised their price target on shares of Alcobra Ltd from $30.00 to $40.00 in a research note to investors on Tuesday, October 8th. They now have a “buy” rating on the stock.
Alcobra Ltd (NASDAQ:ADHD) opened at 17.06 on Wednesday. Alcobra Ltd has a 52-week low of $6.50 and a 52-week high of $26.96. The stock’s 50-day moving average is $16.9 and its 200-day moving average is $13.35. The company’s market cap is $189.8 million.
Alcobra Ltd (NASDAQ:ADHD) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.28) earnings per share for the quarter.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (NASDAQ:ADHD), a common and morbid neuropsychiatric condition in children and adults.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.